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Introduction: Interindividual variability in drug efficacy and toxicity 
can be partly attributed to genetic variation in metabolic enzymes, 
such as CYP2D6. The administration of probe substrates such as 
debrisoquine has been widely used in vivo to phenotype CYP2D6 
metabolic activity. Recently, it was revealed that debrisoquine is also 
a substrate for the OCT1 uptake transporter. Therefore, the principal 
focus of this study was to analyze the misphenotyping that may arise 
in the complex situation, where drugs are substrates to both poly-
morphic enzymes and hepatic uptake transporters.
Patients (or Materials) and Methods: A physiologically based phar-
macokinetic modeling and simulation approach was carried out using 
the Simcyp Simulator (v12). A virtual study population (n = 1000) 
was generated including extensive, poor, and ultrarapid CYP2D6 
metabolizers (86.5%, 8.2%, and 5.3% of the population, respec-
tively). CYP2D6 activity was phenotyped using dextromethorphan 
as a probe substrate and monitoring indirect metrics such as the 
urinary recovery or plasma area under the curve metabolite/drug 
(dextrorphan/dextromethorphan) ratios. Multimodality in the fre-
quency distribution of these metrics in the study population was 
assessed with the NTV (normal test variable) graphical method. 
Using a permeability-limited liver model and gradually decreasing the 
influx of the probe substrate into the liver, we investigated the effects 
of this decrease on the modality of the metrics frequency distribution.
Results: Phenotyping successfully identified a clear multimodal fre-
quency distribution in the study population with regard to CYP2D6 
activity, when no hepatic permeability restrictions are applied to the 
probe substrate. However, when the uptake of the probe substrate 
into the liver is not passive but mainly transporter-mediated, the 
multimodality on the frequency distribution was clearly affected, 
confounding the distinction between the poor and extensive metabo-
lizers. Specifically, when the contribution of the active uptake to 
total uptake was > 90%, multimodality was distorted to a unimodal 
frequency distribution.
Conclusion: In conclusion, the findings suggest that when using 
a probe drug to phenotype the activity of a metabolic enzyme the 
hepatic permeability characteristics of the compound should be 
also considered. When uptake of the probe drug is predominately 
transporter mediated, influx into hepatocytes and not metabolism 
is the step that mostly contributes to the phenotype. Taking also 
into account that uptake transporters can also be polymorphically 
expressed the possibility that transporter variation can produce a 
flawed perception of enzyme activity should not be neglected.
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Introduction: Genetic variants of CYP2D6 may have an effect on 
drug efficiency and toxicity; those variants have not been extensively 
evaluated in Mexican indigenous populations. We determined the 
CYP2D6 allele distribution Amerindian from northwest of Mexico.
Patients (or Materials) and Methods: A total of 508 Amerindians 
from 8 ethnic groups were evaluated through both (1) genotyping of 
CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41, and copy number 
by real time-PCR and (2) amplification of entire CYP2D6 gene by 
XL-PCR for CYP2D6*5 and multiplication alleles.
Results: The CYP2D6*2 was the most frequent in these populations 
(0.05–0.28). The CYP2D6*4 was found with the highest values in 
Seris and Tarahumaras (0.21 and 0.11, respectively) and in Mayos, 
Huicholes, Guarijíos, Coras, and Tepehuanos the frequencies were 
of 0.08, 0.07, 0.03, 0.01, and 0.003, respectively. CYP2D6*5 was 
observed in the Tepehuanos (0.004), Mexicaneros (0.013), Coras 
(0.012), and Tarahumaras (0.034). The CYP2D6*6 was presented 
only in Mayos (0.034) and the CYP2D6*10 only in Tarahumaras 
(0.007).CYP2D6*41 allele was identified in Tepehuanos (0.004), 
Mayos (0.03), Tarahumaras (0.04), and Coras (0.01). The 
CYP2D6*3, *17, *35 and *29 variants were not detected. The fre-
quency of multiplications of functional alleles was in a range of 0.043 
to 0.10. Only 1 Tarahumara subject (1.35%) was homozygous for 
2 inactive alleles (*4/*5).
Conclusion: Our data share a CYP2D6 polymorphic pattern similar 
to other studies in Amerindian groups. The information obtained 
may be useful for generating drug therapy strategies tailored to the 
indigenous population of Mexico.
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Introduction: Major depressive disorder (MDD) is a prevalent and 
severe psychiatric disease with a highly variable treatment response 
and a poorly understood pathogenesis. The present study is focused 
on to find out the C3435T polymorphism of ABCB1 influence on 
susceptibility to depression and clinical response to citalopram.
Patients (or Materials) and Methods: Patients (n = 54) who met 
the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-IV criteria for MDD were enrolled the study. Control group 
consisted of unrelated volunteers (n = 70). All patients had affirmed 
for once a day administration of citalopram at 8:00 to 9:00 pm during 
the study. Protocol visits were completed at baseline, 1st, 2nd, 4th, 
and 6th weeks. The clinical response to citalopram was evaluated 
by psychiatrists with 17-item Hamilton Rating Scale for Depression 
